+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Benign Prostatic Hyperplasia - Pipeline Review, H2 2019

  • ID: 4894186
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 110 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aphios Corp
  • Curadis GmbH
  • GemVax & KAEL Co Ltd
  • Kolmar Pharma Co Ltd
  • Mezzion Pharma Co Ltd
  • Ono Pharmaceutical Co Ltd
  • MORE
Benign Prostatic Hyperplasia - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Benign Prostatic Hyperplasia - Pipeline Review, H2 2019, provides an overview of the Benign Prostatic Hyperplasia (Male Health) pipeline landscape.

Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Benign Prostatic Hyperplasia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Benign Prostatic Hyperplasia (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 8, 4, 5, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Benign Prostatic Hyperplasia (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Benign Prostatic Hyperplasia (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Benign Prostatic Hyperplasia (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Benign Prostatic Hyperplasia (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aphios Corp
  • Curadis GmbH
  • GemVax & KAEL Co Ltd
  • Kolmar Pharma Co Ltd
  • Mezzion Pharma Co Ltd
  • Ono Pharmaceutical Co Ltd
  • MORE
Introduction
Report Coverage
Benign Prostatic Hyperplasia - Overview
Benign Prostatic Hyperplasia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Benign Prostatic Hyperplasia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development
Aphios Corp
Aquestive Therapeutics Inc
ASKA Pharmaceutical Co Ltd
BCWorld Pharm Co Ltd
Chong Kun Dang Pharmaceutical Corp
Curadis GmbH
DongKoo Bio & Pharma Co Ltd
Dongkook Pharmaceutical Co Ltd
Everon Biosciences Inc
GemVax & KAEL Co Ltd
Health Ever Bio-Tech Co Ltd
Huons Co Ltd
Jeil Pharmaceutical Co Ltd
Kissei Pharmaceutical Co Ltd
Kolmar Pharma Co Ltd
Meiji Seika Pharma Co Ltd
Mezzion Pharma Co Ltd
Nymox Pharmaceutical Corp
Ono Pharmaceutical Co Ltd
Sophiris Bio Inc
Sun Pharma Advanced Research Company Ltd
ValiRx Plc
Veru Inc
XuanZhu Pharma Co Ltd
Yuyu Pharma Inc
Benign Prostatic Hyperplasia - Drug Profiles
(alfuzosin hydrochloride ER + tadalafil) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(dutasteride + tadalafil) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(finasteride + tadalafil) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(solifenacin + tamsulosin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AKP-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCWPE-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CR-1447 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fexapotide triflutate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KKM-1202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MCS-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-7300243 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RDG-17028 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-0131632 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
silodosin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sirolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sperol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
talaporfin sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tamsulosin hydrochloride DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tamsulosin hydrochloride XR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tamsulosin SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tamsulosin SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tertomotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
topsalysin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
udenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAL-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XZP-5849 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YY-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Benign Prostatic Hyperplasia - Dormant Projects
Benign Prostatic Hyperplasia - Discontinued Products
Benign Prostatic Hyperplasia - Product Development Milestones
Featured News & Press Releases
Jun 26, 2019: Veru announces successful completion of pre-NDA meeting with FDA for tadfin (tadalafil 5mg and finasteride 5mg) combination for the treatment of benign prostatic hyperplasia
Apr 16, 2019: Nymox reports pre-NDA CMC meeting with the FDA
Apr 05, 2019: Gemvax & Kael’s wins nod for P3 trial of benign prostatic hyperplasia treatment
Jan 31, 2019: ValiRx received Russian Federation & Chinese patent grant allowances for therapeutic compound, VAL301
Jan 15, 2019: New peer review article entitled “efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia” published in Therapeutic Advances in Urology
Jan 14, 2019: Veru Plans to Submit NDA in 2019
Dec 03, 2018: Veru announces first patient dosed in bioequivalence clinical trial for combination Tadalafil - Finasteride tablet for benign prostatic hyperplasia
Nov 15, 2018: Recordati receives positive CHMP opinion for generic medicine Silodosin for the treatment of Benign Prostatic Hyperplasia
Oct 03, 2018: Nymox reports safety benefits of Fexapotide treatments for prostate cancer and benign prostatic hyperplasia
Jun 07, 2018: NYMOX Successfully Achieves Manufacturing Scale-Up
May 22, 2018: Fexapotide Triflutate Pivotal Phase 3 Study Results Presented and Discussed at American Urological Association Annual Meeting in San Francisco
May 11, 2018: Nymox’s Fexapotide Featured in Broadcast of Grand Rounds in Urology
May 02, 2018: Nymox Announces Fexapotide Drug Symposium at AUA Annual Meeting San Francisco May 20
Apr 16, 2018: GemVax & KAEL Announces Positive Phase 2 Data on GV1001 for Prostate Hyperplasia
Apr 10, 2018: New Online Commentary in UroToday on Fexapotide BPH Clinical Trial Results Publication in World Journal of Urology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Benign Prostatic Hyperplasia, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Benign Prostatic Hyperplasia - Pipeline by Aphios Corp, H2 2019
Benign Prostatic Hyperplasia - Pipeline by Aquestive Therapeutics Inc, H2 2019
Benign Prostatic Hyperplasia - Pipeline by ASKA Pharmaceutical Co Ltd, H2 2019
Benign Prostatic Hyperplasia - Pipeline by BCWorld Pharm Co Ltd, H2 2019
Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019
Benign Prostatic Hyperplasia - Pipeline by Curadis GmbH, H2 2019
Benign Prostatic Hyperplasia - Pipeline by DongKoo Bio & Pharma Co Ltd, H2 2019
Benign Prostatic Hyperplasia - Pipeline by Dongkook Pharmaceutical Co Ltd, H2 2019
Benign Prostatic Hyperplasia - Pipeline by Everon Biosciences Inc, H2 2019
Benign Prostatic Hyperplasia - Pipeline by GemVax & KAEL Co Ltd, H2 2019
Benign Prostatic Hyperplasia - Pipeline by Health Ever Bio-Tech Co Ltd, H2 2019
Benign Prostatic Hyperplasia - Pipeline by Huons Co Ltd, H2 2019
Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2019
Benign Prostatic Hyperplasia - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2019
Benign Prostatic Hyperplasia - Pipeline by Kolmar Pharma Co Ltd, H2 2019
Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co Ltd, H2 2019
Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co Ltd, H2 2019
Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corp, H2 2019
Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio Inc, H2 2019
Benign Prostatic Hyperplasia - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2019
Benign Prostatic Hyperplasia - Pipeline by ValiRx Plc, H2 2019
Benign Prostatic Hyperplasia - Pipeline by Veru Inc, H2 2019
Benign Prostatic Hyperplasia - Pipeline by XuanZhu Pharma Co Ltd, H2 2019
Benign Prostatic Hyperplasia - Pipeline by Yuyu Pharma Inc, H2 2019
Benign Prostatic Hyperplasia - Dormant Projects, H2 2019
Benign Prostatic Hyperplasia - Dormant Projects, H2 2019 (Contd..1), H2 2019
Benign Prostatic Hyperplasia - Dormant Projects, H2 2019 (Contd..2), H2 2019
Benign Prostatic Hyperplasia - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Benign Prostatic Hyperplasia, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aphios Corp
  • Aquestive Therapeutics Inc
  • ASKA Pharmaceutical Co Ltd
  • BCWorld Pharm Co Ltd
  • Chong Kun Dang Pharmaceutical Corp
  • Curadis GmbH
  • DongKoo Bio & Pharma Co Ltd
  • Dongkook Pharmaceutical Co Ltd
  • Everon Biosciences Inc
  • GemVax & KAEL Co Ltd
  • Health Ever Bio-Tech Co Ltd
  • Huons Co Ltd
  • Jeil Pharmaceutical Co Ltd
  • Kissei Pharmaceutical Co Ltd
  • Kolmar Pharma Co Ltd
  • Meiji Seika Pharma Co Ltd
  • Mezzion Pharma Co Ltd
  • Nymox Pharmaceutical Corp
  • Ono Pharmaceutical Co Ltd
  • Sophiris Bio Inc
  • Sun Pharma Advanced Research Company Ltd
  • ValiRx Plc
  • Veru Inc
  • XuanZhu Pharma Co Ltd
  • Yuyu Pharma Inc
Note: Product cover images may vary from those shown
Adroll
adroll